TrimRx's Blog

Wegovy (semaglutide 2.4mg) delivers 14.9% mean weight loss in obesity treatment trials — here’s the dosing protocol, side effect timeline, and what most

Wegovy reduces LDL cholesterol by 6–9% and triglycerides by 13–20% in clinical trials, independent of weight loss. Learn how the medication impacts

Wegovy received FDA approval for obstructive sleep apnea in 2024, showing 25–35% reduction in AHI scores. How the GLP-1 mechanism works beyond weight loss

Wegovy reduces liver fat by 59% in NAFLD patients via GLP-1 receptor modulation. Learn mechanisms, dose protocols, and realistic outcomes.

Wegovy reduces major cardiovascular events by 20% in high-risk patients — here’s the mechanism, trial data, and what cardiologists actually recommend.

Wegovy reduces blood pressure by 3–7 mmHg systolic through weight loss and improved vascular function — here’s what patients need to know about the effect.

Wegovy reduces liver fat by 24–38% in NAFLD patients through direct hepatic GLP-1 receptor activation — not just weight loss. Here’s the mechanism

Wegovy (semaglutide) reduces systemic inflammation markers like CRP and IL-6 by 20–30% through weight loss and direct anti-inflammatory pathways.

Wegovy’s cancer risk stems from animal thyroid tumors observed in rodent studies — not human clinical trials. Here’s what patients need to know.